Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL37496 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL365960 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL600583 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372189 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372671 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8146438 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL13684439 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20917177 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21753855 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372698 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2019-07-18 | — | — | US | claimed |
| CN-109414442-A | (S) liquid preparation of-N- (5- ((R) -2- (2,5- difluorophenyl)-pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide | 洛克索肿瘤学股份有限公司 | 2019-03-01 | — | — | CN | claimed |
| EP-3439663-A1 | METHODS OF TREATING PEDIATRIC CANCERS | Loxo Oncology Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| EP-3439662-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | Loxo Oncology Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| CN-109310694-A | METHODS OF TREATING PEDIATRIC CANCERS | 洛克索肿瘤学股份有限公司 | 2019-02-05 | — | — | CN | claimed |
| US-10137127-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | LOXO ONCOLOGY, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-20170296544-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2017-10-19 | — | — | US | claimed |
| WO-2017176744-A1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY, INC. (US) | 2017-10-12 | — | — | WO | claimed |
| WO-2017176751-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. (US) | 2017-10-12 | — | — | WO | claimed |
| US-20170224827-A1 | STABLE PRESERVATIVE FREE OPHTHALMIC FORMULATIONS OF OPIOID ANTAGONISTS | IMUNEKS FARMA ILAC SANAYI VE TICARET ANONIM SIRKET (TR) | 2017-08-10 | — | — | US | claimed |
| CN-101172104-A | Processes of making and using pharmaceutical formulations of antineoplastic agents | SCHERING CORP (US) | 2008-05-07 | — | — | CN | claimed |
| CN-100346784-C | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| CN-1635871-A | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | MEN1 3316/4885ALDH1A1 1446/4885HMGCR 4265/4885 |
| US-10137127-B2 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | IL5, IL1A, RRP15 | MEN1 3316/4885ALDH1A1 1446/4885HMGCR 4265/4885 |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | MEN1 237/4885ALDH1A1 3247/4885HMGCR 1644/4885 |
| US-20170296544-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | MEN1 3316/4885ALDH1A1 1446/4885HMGCR 4265/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | MEN1 139/4885ALDH1A1 1296/4885HMGCR 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.